Global Alzheimer's Disease Therapeutics and Diagnostics Market 2022-2028: Emergence of New Diagnostic Technologies & Growing Number of Pipeline Drugs?Presents Opportunities

25 Aug 2022
www.prnewswire.com
DUBLIN, Aug. 25, 2022 /PRNewswire/ -- The "Global Alzheimer'S Disease Therapeutics and Diagnostics Market 2022-2028" report has been added to
ResearchAndMarkets.com's offering.
MARKET OUTLOOK
The publisher estimates the global AlzheimerAlzheimer's disease therapeutics and diagnostics market to grow with a CAGR of 6.98% in the years 2022-2028.
The high prevalence of Alzheimer's disease (AD) and the growing elderly populace are key factors driving the growth of this market. The elderly population is at an increased risk of developing this disease, which is expected to aid the demand for therapeutics and diagnostics. However, stringent regulations by the government, as well as the failure of the late-stage drugs in clinical trials, are hampering the growth of this industry. On the bright side, the emergence of novel diagnostic technologies for AD treatment is creating new avenues for the market's development.
The global market for Alzheimer's therapeutics and diagnostics spans Europe, the Asia-Pacific, Latin America, the Middle East and Africa, and North America.
North America held the largest share in the global market in 2021, and is anticipated to maintain its lead by the end of the forecast period. Developed nations, such as the US and Canada, are considered in the market in this region. Factors such as the rising geriatric population and the growing burden of Alzheimer's disease contribute to the growth of the market in North America. Statistics indicate that 1 in every 9 people in the US, aged 65 years or older, is affected by AD. This has enhanced the demand for developing novel therapeutics and diagnostics for Alzheimer's.
Market Drivers
Rise in the Elderly Population
Market Challenges
Failure of Late-Stage Drugs
Stringent Government Regulations
Market Opportunities
Emergence of New Diagnostic Technologies
Growing Number of Pipeline Drugs
Key Topics Covered:
1. Global Alzheimer's Disease Therapeutics and Diagnostics Market - Summary
2. Industry Outlook
3. Global Alzheimer's Disease Therapeutics and Diagnostics Market - by Therapeutics
3.1. By Drug Type
3.1.1. Marketed Drugs
3.1.2. Pipeline Drugs
3.2. By Disease Stage
3.2.1. Late Stage: Severe Ad
3.2.2. Early/Middle Stage: Mild to Moderate Ad
3.2.3. Prodromal Stage
3.3.1. Branded
3.3.2. Generic
4. Global Alzheimer's Disease Therapeutics and Diagnostics Market - by Diagnostics
4.1. Lumbar Puncture Test
4.2. Positron Emission Tomography
4.3. Electroencephalography
4.4. Magnetic Resonance Imaging
4.7. Other Diagnostics
5. Global Alzheimer's Disease Therapeutics and Diagnostics Market - Regional Outlook
Companies Mentioned
Allergan plc (Acquired by Abbvie)
Merck and Co
Johnson and Johnson
For more information about this report visit https://www.researchandmarkets.com/r/fe9ywz
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.